The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...

Shares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the ...

Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) fell 3.4% following a recent Wall Street Journal report indicating that the ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Gilead Sciences recently experienced a significant price movement, rising 24% in the last quarter. This upward trajectory coincides with positive developments in its HIV treatment portfolio ...

Investing.com -- Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...